Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future

Yonas E. Geda; Lon S. Schneider; Laura N. Gitlin; David S. Miller; Gwenn S. Smith; Joanne Bell; Jovier Evans; Michael Lee; Anton Porsteinsson; Krista L. Lanctôt; Paul B. Rosenberg; David L. Sultzer; Paul T. Francis; Henry Brodaty; Prasad P. Padala; Chiadikaobi U. Onyike; Luis Agüera Ortiz; Sonia Ancoli-Israel; Donald L. Bliwise; Jennifer L. Martin; Michael V. Vitiello; Kristine Yaffe; Phyllis C. Zee; Nathan Herrmann; Robert A. Sweet; Clive Ballard; Ni A. Khin; Cara Alfaro; Patrick S. Murray; Susan Schultz; Constantine G. Lyketsos

doi:10.1016/j.jalz.2012.12.001

Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future

Yonas E. Geda, Lon S. Schneider, Laura N. Gitlin, David S. Miller, Gwenn S. Smith, Joanne Bell, Jovier Evans, Michael Lee, Anton Porsteinsson, Krista L. Lanctôt, Paul B. Rosenberg, David L. Sultzer, Paul T. Francis, Henry Brodaty, Prasad P. Padala, Chiadikaobi U. Onyike, Luis Agüera Ortiz, Sonia Ancoli-Israel, Donald L. Bliwise, Jennifer L. MartinMichael V. Vitiello, Kristine Yaffe, Phyllis C. Zee, Nathan Herrmann, Robert A. Sweet, Clive Ballard, Ni A. Khin, Cara Alfaro, Patrick S. Murray, Susan Schultz, Constantine G. Lyketsos

Neuroscience

Research output: Contribution to journal › Article › peer-review

277 Scopus citations

Abstract

Neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) are widespread and disabling. This has been known since Dr. Alois Alzheimer's first case, Frau Auguste D., presented with emotional distress and delusions of infidelity/excessive jealousy, followed by cognitive symptoms. Being cognizant of this, in 2010 the Alzheimer's Association convened a research roundtable on the topic of NPS in AD. A major outcome of the roundtable was the founding of a Professional Interest Area (PIA) within the International Society to Advance Alzheimer's Research and Treatment (ISTAART). The NPS-PIA has prepared a series of documents that are intended to summarize the literature and provide more detailed specific recommendations for NPS research. This overview paper is the first of these living documents that will be updated periodically as the science advances. The overview is followed by syndrome-specific synthetic reviews and recommendations prepared by NPS-PIA workgroups on depression, apathy, sleep, agitation, and psychosis.

Original language	English (US)
Pages (from-to)	602-608
Number of pages	7
Journal	Alzheimer's and Dementia
Volume	9
Issue number	5
DOIs	https://doi.org/10.1016/j.jalz.2012.12.001
State	Published - Sep 2013

Bibliographical note

Funding Information:
The authors thank Dr. Michelle M. Mielke for her helpful comments and feedback on early drafts of this manuscript. Dr. Geda was supported by NIMH grant K01-MH68351 , NIA grant U01-AG006786 (the Mayo Clinic Study of Aging), National Center for Research Resources grant RR024150 (Mayo Clinic CTSA [Career Transition Award]), the Robert Wood Johnson Foundation (Harold Amos Scholar), and the European Union Regional Development Fund (Project FNUSA-ICRC: CZ.1.05/1.1.00/02.0123). Dr. Schneider reports being an editor on the Cochrane Collaboration Dementia and Cognitive Improvement Group, which oversees systematic reviews of drugs for cognitive impairment and dementia. He received a grant from the Alzheimer's Association for a registry for dementia and cognitive impairment trials; he is also in receipt of grant or research support from Baxter , Elan Pharmaceuticals , Johnson & Johnson , Eli Lilly , Myriad , Novartis , and Pfizer . He has served as a consultant for or received consulting fees from Abbott Laboratories, AC Immune, Allergan, Allon, the Alzheimer Drug Discovery Foundation, AstraZeneca, Bristol-Myers Squibb, Elan, Eli Lilly, Exonhit, Forest, GlaxoSmithKline, Ipsen Pharmaceuticals, Johnson & Johnson, Lundbeck, Myriad, Medavante, Medivation, Merck, Merz, Novartis, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, Schwabe, Toyama, and Transition Therapeutics. Dr. Gitlin was supported by NIMH grants R24-MH074779 , R01-MH079814 , and RC1-MH090770-01 and Alzheimer's Association grant IIRG-07-28686 and served on the Phillips Life Line Falls Advisory Board. Dr. Miller is a full-time employee of Bracket. Dr. Lyketsos was supported by the Johns Hopkins Alzheimer's Disease Research Center ( P50-AG005146 ). He has received grant support (research or CME) from NIMH , NIA , the Associated Jewish Federation of Baltimore , the Weinberg Foundation , Forest , GlaxoSmithKline , Eisai , Pfizer , AstraZeneca , Lilly , Ortho-McNeil , Bristol-Myers , Novartis , the National Football League , Elan , and Functional Neuromodulation Inc . He has served as consultant/advisor for AstraZeneca, GlaxoSmithKline, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Lilly, Pfizer, Genentech, Elan, the NFL Players Association, the NFL Benefits Office, Avanir, and Zinfandel. He has also received honorarium or travel support from Pfizer, Forest, GlaxoSmithKline, and Health Monitor. Supplementary data Appendix A Appendix B Appendix C Appendix D Appendix E

Keywords

Agitation/aggression
Alzheimer's disease
Apathy
Behavioral and psychological symptoms of dementia
Delusions
Dementia
Depression
Hallucinations
Mild behavioral impairment
Mild cognitive impairment
Neuropsychiatric symptoms
Psychosis
Sleep disorders

Access

10.1016/j.jalz.2012.12.001

OpenUrl availability

Full text

Cite this

Geda, Y. E., Schneider, L. S., Gitlin, L. N., Miller, D. S., Smith, G. S., Bell, J., Evans, J., Lee, M., Porsteinsson, A., Lanctôt, K. L., Rosenberg, P. B., Sultzer, D. L., Francis, P. T., Brodaty, H., Padala, P. P., Onyike, C. U., Ortiz, L. A., Ancoli-Israel, S., Bliwise, D. L., ... Lyketsos, C. G. (2013). Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future. Alzheimer's and Dementia, 9(5), 602-608. https://doi.org/10.1016/j.jalz.2012.12.001

Geda, YE, Schneider, LS, Gitlin, LN, Miller, DS, Smith, GS, Bell, J, Evans, J, Lee, M, Porsteinsson, A, Lanctôt, KL, Rosenberg, PB, Sultzer, DL, Francis, PT, Brodaty, H, Padala, PP, Onyike, CU, Ortiz, LA, Ancoli-Israel, S, Bliwise, DL, Martin, JL, Vitiello, MV, Yaffe, K, Zee, PC, Herrmann, N, Sweet, RA, Ballard, C, Khin, NA, Alfaro, C, Murray, PS, Schultz, S & Lyketsos, CG 2013, 'Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future', Alzheimer's and Dementia, vol. 9, no. 5, pp. 602-608. https://doi.org/10.1016/j.jalz.2012.12.001

@article{498b254cf23f42ffbad794676fedec2a,

title = "Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future",

abstract = "Neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) are widespread and disabling. This has been known since Dr. Alois Alzheimer's first case, Frau Auguste D., presented with emotional distress and delusions of infidelity/excessive jealousy, followed by cognitive symptoms. Being cognizant of this, in 2010 the Alzheimer's Association convened a research roundtable on the topic of NPS in AD. A major outcome of the roundtable was the founding of a Professional Interest Area (PIA) within the International Society to Advance Alzheimer's Research and Treatment (ISTAART). The NPS-PIA has prepared a series of documents that are intended to summarize the literature and provide more detailed specific recommendations for NPS research. This overview paper is the first of these living documents that will be updated periodically as the science advances. The overview is followed by syndrome-specific synthetic reviews and recommendations prepared by NPS-PIA workgroups on depression, apathy, sleep, agitation, and psychosis.",

keywords = "Agitation/aggression, Alzheimer's disease, Apathy, Behavioral and psychological symptoms of dementia, Delusions, Dementia, Depression, Hallucinations, Mild behavioral impairment, Mild cognitive impairment, Neuropsychiatric symptoms, Psychosis, Sleep disorders",

author = "Geda, {Yonas E.} and Schneider, {Lon S.} and Gitlin, {Laura N.} and Miller, {David S.} and Smith, {Gwenn S.} and Joanne Bell and Jovier Evans and Michael Lee and Anton Porsteinsson and Lanct{\^o}t, {Krista L.} and Rosenberg, {Paul B.} and Sultzer, {David L.} and Francis, {Paul T.} and Henry Brodaty and Padala, {Prasad P.} and Onyike, {Chiadikaobi U.} and Ortiz, {Luis Ag{\"u}era} and Sonia Ancoli-Israel and Bliwise, {Donald L.} and Martin, {Jennifer L.} and Vitiello, {Michael V.} and Kristine Yaffe and Zee, {Phyllis C.} and Nathan Herrmann and Sweet, {Robert A.} and Clive Ballard and Khin, {Ni A.} and Cara Alfaro and Murray, {Patrick S.} and Susan Schultz and Lyketsos, {Constantine G.}",

note = "Funding Information: The authors thank Dr. Michelle M. Mielke for her helpful comments and feedback on early drafts of this manuscript. Dr. Geda was supported by NIMH grant K01-MH68351 , NIA grant U01-AG006786 (the Mayo Clinic Study of Aging), National Center for Research Resources grant RR024150 (Mayo Clinic CTSA [Career Transition Award]), the Robert Wood Johnson Foundation (Harold Amos Scholar), and the European Union Regional Development Fund (Project FNUSA-ICRC: CZ.1.05/1.1.00/02.0123). Dr. Schneider reports being an editor on the Cochrane Collaboration Dementia and Cognitive Improvement Group, which oversees systematic reviews of drugs for cognitive impairment and dementia. He received a grant from the Alzheimer's Association for a registry for dementia and cognitive impairment trials; he is also in receipt of grant or research support from Baxter , Elan Pharmaceuticals , Johnson & Johnson , Eli Lilly , Myriad , Novartis , and Pfizer . He has served as a consultant for or received consulting fees from Abbott Laboratories, AC Immune, Allergan, Allon, the Alzheimer Drug Discovery Foundation, AstraZeneca, Bristol-Myers Squibb, Elan, Eli Lilly, Exonhit, Forest, GlaxoSmithKline, Ipsen Pharmaceuticals, Johnson & Johnson, Lundbeck, Myriad, Medavante, Medivation, Merck, Merz, Novartis, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, Schwabe, Toyama, and Transition Therapeutics. Dr. Gitlin was supported by NIMH grants R24-MH074779 , R01-MH079814 , and RC1-MH090770-01 and Alzheimer's Association grant IIRG-07-28686 and served on the Phillips Life Line Falls Advisory Board. Dr. Miller is a full-time employee of Bracket. Dr. Lyketsos was supported by the Johns Hopkins Alzheimer's Disease Research Center ( P50-AG005146 ). He has received grant support (research or CME) from NIMH , NIA , the Associated Jewish Federation of Baltimore , the Weinberg Foundation , Forest , GlaxoSmithKline , Eisai , Pfizer , AstraZeneca , Lilly , Ortho-McNeil , Bristol-Myers , Novartis , the National Football League , Elan , and Functional Neuromodulation Inc . He has served as consultant/advisor for AstraZeneca, GlaxoSmithKline, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Lilly, Pfizer, Genentech, Elan, the NFL Players Association, the NFL Benefits Office, Avanir, and Zinfandel. He has also received honorarium or travel support from Pfizer, Forest, GlaxoSmithKline, and Health Monitor. Supplementary data Appendix A Appendix B Appendix C Appendix D Appendix E ",

year = "2013",

month = sep,

doi = "10.1016/j.jalz.2012.12.001",

language = "English (US)",

volume = "9",

pages = "602--608",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "Elsevier Inc.",

number = "5",

}

TY - JOUR

T1 - Neuropsychiatric symptoms in Alzheimer's disease

T2 - Past progress and anticipation of the future

AU - Geda, Yonas E.

AU - Schneider, Lon S.

AU - Gitlin, Laura N.

AU - Miller, David S.

AU - Smith, Gwenn S.

AU - Bell, Joanne

AU - Evans, Jovier

AU - Lee, Michael

AU - Porsteinsson, Anton

AU - Lanctôt, Krista L.

AU - Rosenberg, Paul B.

AU - Sultzer, David L.

AU - Francis, Paul T.

AU - Brodaty, Henry

AU - Padala, Prasad P.

AU - Onyike, Chiadikaobi U.

AU - Ortiz, Luis Agüera

AU - Ancoli-Israel, Sonia

AU - Bliwise, Donald L.

AU - Martin, Jennifer L.

AU - Vitiello, Michael V.

AU - Yaffe, Kristine

AU - Zee, Phyllis C.

AU - Herrmann, Nathan

AU - Sweet, Robert A.

AU - Ballard, Clive

AU - Khin, Ni A.

AU - Alfaro, Cara

AU - Murray, Patrick S.

AU - Schultz, Susan

AU - Lyketsos, Constantine G.

N1 - Funding Information: The authors thank Dr. Michelle M. Mielke for her helpful comments and feedback on early drafts of this manuscript. Dr. Geda was supported by NIMH grant K01-MH68351 , NIA grant U01-AG006786 (the Mayo Clinic Study of Aging), National Center for Research Resources grant RR024150 (Mayo Clinic CTSA [Career Transition Award]), the Robert Wood Johnson Foundation (Harold Amos Scholar), and the European Union Regional Development Fund (Project FNUSA-ICRC: CZ.1.05/1.1.00/02.0123). Dr. Schneider reports being an editor on the Cochrane Collaboration Dementia and Cognitive Improvement Group, which oversees systematic reviews of drugs for cognitive impairment and dementia. He received a grant from the Alzheimer's Association for a registry for dementia and cognitive impairment trials; he is also in receipt of grant or research support from Baxter , Elan Pharmaceuticals , Johnson & Johnson , Eli Lilly , Myriad , Novartis , and Pfizer . He has served as a consultant for or received consulting fees from Abbott Laboratories, AC Immune, Allergan, Allon, the Alzheimer Drug Discovery Foundation, AstraZeneca, Bristol-Myers Squibb, Elan, Eli Lilly, Exonhit, Forest, GlaxoSmithKline, Ipsen Pharmaceuticals, Johnson & Johnson, Lundbeck, Myriad, Medavante, Medivation, Merck, Merz, Novartis, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, Schwabe, Toyama, and Transition Therapeutics. Dr. Gitlin was supported by NIMH grants R24-MH074779 , R01-MH079814 , and RC1-MH090770-01 and Alzheimer's Association grant IIRG-07-28686 and served on the Phillips Life Line Falls Advisory Board. Dr. Miller is a full-time employee of Bracket. Dr. Lyketsos was supported by the Johns Hopkins Alzheimer's Disease Research Center ( P50-AG005146 ). He has received grant support (research or CME) from NIMH , NIA , the Associated Jewish Federation of Baltimore , the Weinberg Foundation , Forest , GlaxoSmithKline , Eisai , Pfizer , AstraZeneca , Lilly , Ortho-McNeil , Bristol-Myers , Novartis , the National Football League , Elan , and Functional Neuromodulation Inc . He has served as consultant/advisor for AstraZeneca, GlaxoSmithKline, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Lilly, Pfizer, Genentech, Elan, the NFL Players Association, the NFL Benefits Office, Avanir, and Zinfandel. He has also received honorarium or travel support from Pfizer, Forest, GlaxoSmithKline, and Health Monitor. Supplementary data Appendix A Appendix B Appendix C Appendix D Appendix E

PY - 2013/9

Y1 - 2013/9

N2 - Neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) are widespread and disabling. This has been known since Dr. Alois Alzheimer's first case, Frau Auguste D., presented with emotional distress and delusions of infidelity/excessive jealousy, followed by cognitive symptoms. Being cognizant of this, in 2010 the Alzheimer's Association convened a research roundtable on the topic of NPS in AD. A major outcome of the roundtable was the founding of a Professional Interest Area (PIA) within the International Society to Advance Alzheimer's Research and Treatment (ISTAART). The NPS-PIA has prepared a series of documents that are intended to summarize the literature and provide more detailed specific recommendations for NPS research. This overview paper is the first of these living documents that will be updated periodically as the science advances. The overview is followed by syndrome-specific synthetic reviews and recommendations prepared by NPS-PIA workgroups on depression, apathy, sleep, agitation, and psychosis.

AB - Neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) are widespread and disabling. This has been known since Dr. Alois Alzheimer's first case, Frau Auguste D., presented with emotional distress and delusions of infidelity/excessive jealousy, followed by cognitive symptoms. Being cognizant of this, in 2010 the Alzheimer's Association convened a research roundtable on the topic of NPS in AD. A major outcome of the roundtable was the founding of a Professional Interest Area (PIA) within the International Society to Advance Alzheimer's Research and Treatment (ISTAART). The NPS-PIA has prepared a series of documents that are intended to summarize the literature and provide more detailed specific recommendations for NPS research. This overview paper is the first of these living documents that will be updated periodically as the science advances. The overview is followed by syndrome-specific synthetic reviews and recommendations prepared by NPS-PIA workgroups on depression, apathy, sleep, agitation, and psychosis.

KW - Agitation/aggression

KW - Alzheimer's disease

KW - Apathy

KW - Behavioral and psychological symptoms of dementia

KW - Delusions

KW - Dementia

KW - Depression

KW - Hallucinations

KW - Mild behavioral impairment

KW - Mild cognitive impairment

KW - Neuropsychiatric symptoms

KW - Psychosis

KW - Sleep disorders

UR - http://www.scopus.com/inward/record.url?scp=84883557180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883557180&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2012.12.001

DO - 10.1016/j.jalz.2012.12.001

M3 - Article

C2 - 23562430

AN - SCOPUS:84883557180

SN - 1552-5260

VL - 9

SP - 602

EP - 608

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 5

ER -

Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this